Menu
Off-the-shelf immunotherapy for solid tumors
Discovery platform generating first-in-class candidates
We are pioneers in next-generation immuno oncology treatment
Thanks to our proteomics-driven precision & AI-powered prediction approach for a deeper undersanting of cancer complexities.
90% of patients currently undergoing treatment for solid tumors will experience treatment failure and relapse within the next 5 years.
This represents 10 million patients annually,
and is projected to increase by 70% by 2045.
Solid tumors remains the biggest challenge in cancer care
of patients will relapse
Annual mortality Worldwide
Tumor
antigens
Immune cell
Tumor cell
Multiple & evolving targets
Hiding from the immune system
It constantly adapts under therapeutic pressure to express new tumor antigens invisble to the immune system.
Treatments fail to anticipate tumors’ evolution and relapse mechanisms
due to tumor plasticity : a key driver of cancer mortality.
Ensuring the immune system’s education,
to give back to patients the ability to target and destroy evolving tumor cells.
The successful equation to anticipate disease progression
CHARACTERIZED BY MULTI-OMICS ANALYSIS
REGARDLESS OF THEIR EVOLUTION
+150 PRECISION CANCER-RELATED
TARGETS
Strict & AI powered selection of starting material : Allogeneic tumor cell lines
Haptenation and inactivation process leading to non-proliferative immunogenic ghost cells, to initiate a potent immune response against tumor cells.
Exposition to standards of care treatments :
+200 targets expressed, including cancer related antigens, linked to therapeutic pressure and resistances
Multi-omics characterization of targets
matching >5000 patient’s biopsies
See Video here
Celebrating and honoring excellence: accolades from institutions,
associations, and renowned universities driving us forward.
REMAINS A HUGE UNMET NEED WORLDWIDE
incidence
mortality
REMAINS A HUGE UNMET NEED WORLDWIDE
incidence
mortality
We are backed by internationally recognized key scientific opinion leaders. They act as strategic advisors to ensure validation process robustness, and as main ambassadors of our technology, significantly contributing to our publications.
Our team is driven by passion and dedication, working in collaboration to bring innovative therapeutic solutions to patients.
Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system with visible and multi-specific targets
Selection criteria of starting material (Allogeneic tumor cell lines)
Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system with a broad & higher quality range of tumor antigens
